ClinicalTrials.Veeva

Menu

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Novartis logo

Novartis

Status

Completed

Conditions

Somatostatin Receptor-positive GEP-NET

Treatments

Other: Lutathera

Study type

Observational

Funder types

Industry

Identifiers

NCT04946305
CAAA601A12403

Details and patient eligibility

About

This is a prospective, open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Lutathera in patients with somatostatin receptor-positive GEP-NET in the real-world setting in Korea.

Enrollment

89 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients who start Lutathera treatment per clinical judgment, according to the locally approved labeling.

    • somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.
  2. Patients who are willing to provide written informed consent.

Exclusion criteria

  1. Patients with contraindication according to prescribing information for Lutathera in Korea.

Trial design

89 participants in 1 patient group

Lutathera
Description:
Patients administered Lutathera by prescription
Treatment:
Other: Lutathera

Trial contacts and locations

6

Loading...

Central trial contact

Novartis Pharmaceuticals; Novartis Pharmaceuticals

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems